Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398896 | 0.90 | YAP1 (0.49) | TACR1OPRD1OPRK1YAP1CYP4F2 | |
| SCHEMBL4672807 | 0.88 | OPRD1 (0.53) | TACR1OPRD1OPRK1YAP1GPR119 | |
| SCHEMBL8317190 | 0.87 | NOS2 (0.58) | OPRD1OPRK1CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL2587746 | 0.86 | ALDH1A1 (0.50) | OPRD1OPRK1CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL1979306 | 0.84 | YAP1 (0.49) | TACR1OPRD1OPRK1YAP1GPR119 | |
| SCHEMBL5240524 | 0.83 | ALDH1A1 (0.65) | OPRD1OPRK1ALDH1A1ALOX15TSHR | |
| SCHEMBL12168279 | 0.82 | OPRM1 (0.49) | TACR1OPRD1OPRK1YAP1 | |
| SCHEMBL8243407 | 0.82 | OPRM1 (0.49) | TACR1OPRD1OPRK1YAP1 | |
| SCHEMBL4412901 | 0.82 | OPRD1 (0.51) | TACR1OPRD1OPRK1CYP4F2CYP4A11 | |
| SCHEMBL240381 | 0.82 | TSHR (0.57) | TACR1OPRD1OPRK1ALDH1A1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | TACR1 136/4885OPRD1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.